
Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.
Join Sanofi & Regeneron at ATS 2026 at the ADVENT Booth to explore Type 2 inflammation as a key feature underlying both asthma and COPD, through interactive experiences and educational resources.

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.
Explore the impact of type 2 inflammation and airway remodeling on lung function decline in asthma.

Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients